Heparin-induced thrombocytopenia future or investigational therapies: Difference between revisions
Gerald Chi- (talk | contribs) (Created page with "__NOTOC__ {{Heparin-induced thrombocytopenia}} {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] ==Overview== ==Future...") |
Shyam Patel (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Future therapies for HIT focus on use of new oral anticoagulants.<ref name="pmid21740405">{{cite journal| author=Harenberg J, Marx S, Krejczy M, Wehling M| title=New anticoagulants - promising and failed developments. | journal=Br J Pharmacol | year= 2012 | volume= 165 | issue= 2 | pages= 363-72 | pmid=21740405 | doi=10.1111/j.1476-5381.2011.01578.x | pmc=3268190 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21740405 }} </ref> Director factor X inhibitors and newer direct thrombin inhibitors are being studied, but the data is currently in its infancy. Cost-effectiveness analyses will need to be done to determine whether it is appropriate to use these new agents. | |||
==References== | ==References== | ||
Revision as of 03:22, 31 July 2017
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia future or investigational therapies |
|
FDA on Heparin-induced thrombocytopenia future or investigational therapies |
|
CDC on Heparin-induced thrombocytopenia future or investigational therapies |
|
Heparin-induced thrombocytopenia future or investigational therapies in the news |
|
Blogs on Heparin-induced thrombocytopenia future or investigational therapies |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3]
Overview
Future or Investigational Therapies
Future therapies for HIT focus on use of new oral anticoagulants.[1] Director factor X inhibitors and newer direct thrombin inhibitors are being studied, but the data is currently in its infancy. Cost-effectiveness analyses will need to be done to determine whether it is appropriate to use these new agents.
References
- ↑ Harenberg J, Marx S, Krejczy M, Wehling M (2012). "New anticoagulants - promising and failed developments". Br J Pharmacol. 165 (2): 363–72. doi:10.1111/j.1476-5381.2011.01578.x. PMC 3268190. PMID 21740405.